Belantamab Mafodotin + Lenalidomide for Multiple Myeloma
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, you must not have used an investigational drug or certain anti-myeloma therapies within 14 days before starting the study, and you must not have received a monoclonal antibody treatment within 30 days before the study.
What data supports the effectiveness of the drug combination Belantamab Mafodotin and Lenalidomide for treating multiple myeloma?
Is Belantamab Mafodotin + Lenalidomide safe for humans?
Belantamab Mafodotin has been associated with eye-related side effects, such as changes in vision and dry eyes, which are common and sometimes severe. It is only available through a special program due to these risks. Other side effects include low blood platelet levels and infections, but the safety profile is considered manageable with proper monitoring.678910
How is the drug Belantamab Mafodotin + Lenalidomide unique for treating multiple myeloma?
Belantamab Mafodotin is a first-in-class antibody-drug conjugate that targets B-cell maturation antigen (BCMA) on myeloma cells, delivering a powerful cancer-killing agent directly to the tumor. This approach is unique because it combines targeted therapy with a cytotoxic payload, offering a novel mechanism of action compared to traditional treatments for multiple myeloma.810111213
What is the purpose of this trial?
To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.
Research Team
Qaiser Bashir
Principal Investigator
M.D. Anderson Cancer Center
Eligibility Criteria
This trial is for adults aged 18-75 with newly diagnosed multiple myeloma who have had a stem cell transplant. They must be partially responsive to treatment, in good physical condition, and able to follow strict birth control guidelines. People with progressive disease, certain other myeloma types, eye diseases, recent major surgery or known allergies to the drugs can't join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive belantamab mafodotin by vein on Day 1 and lenalidomide by mouth every day of each cycle for maintenance therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Belantamab Mafodotin
- Lenalidomide
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor